ESMO2019 confress 演題レポート Barcelona, Spain 27 Sep - 01 Oct 2019

2019年9月27日~10月1日にスペイン・バルセロナで開催された 2019年 欧州臨床腫瘍学会学術集会(ESMO 2019 Congress)より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。演題レポートの冒頭には、臨床研究の第一線で活躍する監修ドクターのコメントを掲載します。



Proffered Paper Session

Abstract #LBA10

ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation 

Ghassan K. Abou-Alfa, et al.

Abstract #LBA11

Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 ATTRACTION-3 Study

Byoung Chul Cho, et al.

Abstract #LBA30

Analysis of circulating tumor DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration

Julien Taieb, et al.

Abstract #LBA32

Encorafenib plus Cetuximab With or Without Binimetinib for BRAF V600E–Mutant Metastatic Colorectal Cancer: Expanded Results from a Randomized, 3-Arm, Phase III Study vs. the Choice of Either Irinotecan or FOLFIRI plus Cetuximab (BEACON CRC)

Josep Tabernero, et al.

Abstract #LBA33

Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase 3 IMPALA trial

David Cunningham, et al.

Abstract #LBA38

CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC)

Thomas Yau, et al.

Abstract #LBA39

Randomised Efficacy and Safety Results For Atezolizumab (Atezo) + Bevacizumab (Bev) in Patients (pts) With Previously Untreated, Unresectable Hepatocellular Carcinoma (HCC)

Michael Lee, et al.

Abstract #LBA41

Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)

Yoon-Koo Kang, et al.

Abstract #LBA43

Randomized phase 3 ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens

Yoon-Koo Kang, et al.

Abstract #LBA44

Pembrolizumab With or Without Chemotherapy vs Chemotherapy in Patients With Advanced G/GEJ Cancer (GC) Including Outcomes According to Microsatellite Instability-High (MSI-H) Status in KEYNOTE-062

Kohei Shitara, et al.

Poster Discussion Session

Abstract #526PD

TRIUMPH: Primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): A GOZILA Sub-study

Yoshiaki Nakamura, et al.

Abstract #533PD

BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine (C) Bevacizumab (B) plus Atezolizumab (A) or Placebo (P) in Refractory Metastatic Colorectal Cancer (mCRC): An ACCRU Network Study

Niharika B. Mettu, et al.

Abstract #674PD

Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): safety and biomarker data from the ICONIC trial safety run-in

Michael Davidson (London, United Kingdom)

Poster Display Session

Abstract #571P

Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study

Takeshi Nagasaka, et al.

Abstract #790P

A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)

Daisuke Takahari, et al.

Abstract #820P

Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)

Yu Sunakawa, et al.